中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
9期
177-179
,共3页
小分子肝素钙%过敏性紫癜%肾损害%干预效果%Meta分析
小分子肝素鈣%過敏性紫癜%腎損害%榦預效果%Meta分析
소분자간소개%과민성자전%신손해%간예효과%Meta분석
small dose molecular heparin calcic%Henoch-Schonlein purpura%kidney damage%intervention%Meta analysis
目的：应用Meta分析方法，评价小分子肝素钙对过敏性紫癜并发远期肾损害干预效果的。方法检索CNKI、万方、维普、CBM数据库及Cochrane图书馆，手工检索作为辅助，对纳入文献采取质量分析，采用Stata12.1软件行Meta分析。结果4篇文献纳入随机对照临床试验（randomized controlled trials，RCT），样本共670例，其中333例小分子肝素钙治疗组（37例肾损害），337例对照组（44例肾损害），2组无明显差异（RR＝0.89，95％CI：0.59-1.34，P＝0.578）。结论早期应用小分子肝素钙可预防肾损害发生，但其远期干预效果并不明显，仍需通过多中心、大规模RCT做深入研究。
目的：應用Meta分析方法，評價小分子肝素鈣對過敏性紫癜併髮遠期腎損害榦預效果的。方法檢索CNKI、萬方、維普、CBM數據庫及Cochrane圖書館，手工檢索作為輔助，對納入文獻採取質量分析，採用Stata12.1軟件行Meta分析。結果4篇文獻納入隨機對照臨床試驗（randomized controlled trials，RCT），樣本共670例，其中333例小分子肝素鈣治療組（37例腎損害），337例對照組（44例腎損害），2組無明顯差異（RR＝0.89，95％CI：0.59-1.34，P＝0.578）。結論早期應用小分子肝素鈣可預防腎損害髮生，但其遠期榦預效果併不明顯，仍需通過多中心、大規模RCT做深入研究。
목적：응용Meta분석방법，평개소분자간소개대과민성자전병발원기신손해간예효과적。방법검색CNKI、만방、유보、CBM수거고급Cochrane도서관，수공검색작위보조，대납입문헌채취질량분석，채용Stata12.1연건행Meta분석。결과4편문헌납입수궤대조림상시험（randomized controlled trials，RCT），양본공670례，기중333례소분자간소개치료조（37례신손해），337례대조조（44례신손해），2조무명현차이（RR＝0.89，95％CI：0.59-1.34，P＝0.578）。결론조기응용소분자간소개가예방신손해발생，단기원기간예효과병불명현，잉수통과다중심、대규모RCT주심입연구。
Objective To evaluate small molecule heparin allergic purpura complicated by long-term kidney damage intervention by Meta analysis.Methods Databases of CNKI,Wanfang,VIP,CBM and Cochrane Library were searched,hand searching as an auxiliary, included studies were assessed by quality of analysis, Meta-analysis was conducted by Stata12.1 software line.Results 4 articles were included in randomized controlled clinical trials (randomized controlled trials, RCT), a sample of 670 cases, 333 cases of small molecule heparin calcium treatment group (37 cases of renal damage has occurred), 337 cases of control group (44 cases of renal damage has occurred), no difference between the 2 groups (RR=0.89, 95% CI:0.59-1.34, P=0.578).Conclusion The early application of small molecular weight heparin calcium can not prevent kidney damage, it needs to do in-depth research by multi-center, large-scale RCT.
